# Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

> **NCT00112723** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 46 (actual)

## Conditions studied

- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- Adult Nodular Sclerosis Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Refractory Multiple Myeloma
- Splenic Marginal Zone Lymphoma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** alvocidib

## Key facts

- **NCT ID:** NCT00112723
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2011-02
- **Final completion:** 2015-11
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Administratively Complete
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112723, "Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00112723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*